Under United States law, the holder of a patent on a brand-name, FDA-approved drug can bring suit for patent infringement against a generic drug manufacturer even before the generic manufacturer brings the drug to market. That right to sue is triggered by the generic manufacturer’s filing of the short-cut application to the FDA to sell